Quantcast

Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference

October 26, 2010

SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ — Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) is scheduled to present at Oppenheimer’s 21st Annual Healthcare Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, November 2, 2010, at 10:15 a.m. Eastern Time.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Live audio webcast of this presentation will be accessible on the Company’s website at www.optimerpharma.com, under the investors section. Replays of this presentation will be available at the same location for 30 days after the presentation.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates under development, fidaxomicin and Pruvel(TM) (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). We recently initiated a rolling submission of our NDA filing to the FDA, and filed a MAA to the EMA (Europe) for fidaxomicin. Pruvel(TM) is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. We plan to have an NDA submitted to the FDA in the first quarter of 2011. Additional information can be found at http://www.optimerpharma.com.


    Contacts

    Optimer Pharmaceuticals, Inc.
    Christina Donaghy, Corporate Communications Manager
    John D. Prunty, Chief Financial Officer & VP Finance
    858-909-0736

    Canale Communications, Inc.
    Jason I. Spark, Senior Vice President
    619-849-6005

SOURCE Optimer Pharmaceuticals, Inc.


Source: newswire



comments powered by Disqus